All Stories

  1. Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma

    Article • British Journal of Haematology, April 2018, Wiley

    Dr Francesco Bertoni, Luciano Cascione, RAFFAELLA GATTA

  2. Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study

    Article • British Journal of Haematology, July 2017, Wiley

    Dr Francesco Bertoni, Luciano Cascione

  3. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma

    Article • British Journal of Haematology, June 2017, Wiley

    Dr Francesco Bertoni, Luciano Cascione, Prof. Emanuele Zucca

  4. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions

    Article • Hematological Oncology, June 2017, Wiley

    Luciano Cascione, Prof. Emanuele Zucca

  5. TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation

    Article • Cancer Research, February 2015, American Association for Cancer Research (AACR)

    Luciano Cascione

  6. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

    Article • Clinical Cancer Research, January 2015, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Luciano Cascione, Prof. Emanuele Zucca

  7. Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Luciano Cascione

  8. Abstract 2604: Characterization of the activity and the mechanism of action of the new retinoid derivative ST5589 in pre-clinical models of lymphomas: involvement of MYC and cell cycle genes

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Luciano Cascione

  9. Abstract 739: The MEK-inhibitor pimasertib in B-cell lymphomas: Evaluation of the pre-clinical activity as single agent or in combination and identification of biomarkers of response

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Luciano Cascione

  10. Circulating miRNA markers show promise as new prognosticators for multiple myeloma

    Article • Leukemia, May 2014, Springer Science + Business Media

    Luciano Cascione

  11. MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer

    Article • Cancer Cell, April 2014, Elsevier

    Luciano Cascione

  12. miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs

    Article • Nucleic Acids Research, March 2014, Oxford University Press (OUP)

    Luciano Cascione

  13. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation

    Article • Proceedings of the National Academy of Sciences, March 2014, Proceedings of the National Academy of Sciences

    Luciano Cascione

  14. Androgen Receptor Status Is a Prognostic Marker in Non-Basal Triple Negative Breast Cancers and Determines Novel Therapeutic Options

    Article • PLoS ONE, February 2014, PLOS

    Luciano Cascione

  15. Microarray Data Analysis: From Preparation To Classification

    Article • December 2013, Wiley

    Luciano Cascione

  16. MIDClass: Microarray Data Classification by Association Rules and Gene Expression Intervals

    Article • PLoS ONE, August 2013, PLOS

    Luciano Cascione

  17. Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARβ and tumor regression

    Article • Proceedings of the National Academy of Sciences, May 2013, Proceedings of the National Academy of Sciences

    Luciano Cascione

  18. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

    Article • The Journal of Cell Biology, April 2013, Rockefeller University Press

    Luciano Cascione

  19. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

    Article • The Journal of Experimental Medicine, April 2013, Rockefeller University Press

    Luciano Cascione

  20. A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model

    Article • Blood, April 2013, American Society of Hematology

    Luciano Cascione

  21. Abstract 1951: miRNA expression profile of Blastic plasmacytoid dendritic cell neoplasm.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Luciano Cascione

  22. Abstract 3061: Micro-RNA signature differences in lung cancer patients with ALK translocation, EGFR mutations and KRAS mutations.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Luciano Cascione

  23. Abstract 1122: In vivo NCL-targeting affects breast cancer aggressiveness through miRNA regulation.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Luciano Cascione

  24. Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer

    Article • PLoS ONE, February 2013, PLOS

    Luciano Cascione

  25. Elucidating the Role of microRNAs in Cancer Through Data Mining Techniques

    Article • December 2012, Springer Science + Business Media

    Luciano Cascione

  26. miR-EdiTar: a database of predicted A-to-I edited miRNA target sites

    Article • Bioinformatics, October 2012, Oxford University Press (OUP)

    Luciano Cascione

  27. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non–small-cell lung cancer through BIM down-regulation

    Article • Proceedings of the National Academy of Sciences, September 2012, Proceedings of the National Academy of Sciences

    Luciano Cascione

  28. Trisomy 12 CLLs progress through NOTCH1 mutations

    Article • Leukemia, August 2012, Springer Science + Business Media

    Luciano Cascione

  29. Regulation of acute graft-versus-host disease by microRNA-155

    Article • Blood, March 2012, American Society of Hematology

    Luciano Cascione

  30. EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

    Article • Nature Reports Stem Cells, December 2011, Springer Science + Business Media

    Luciano Cascione